INTRODUCTION
Hematopoietic cell transplantation (HSCT) recipients are at risk of vaccine-preventable diseases secondary to the immunosuppression involved in transplantation. Currently, strategies to prevent these diseases involve repeated vaccinations post transplantation as well as administration of prophylactic antimicrobial agents targeted against common pathogens.
HSCT recipients, nevertheless, will lose immunity to infections to which they were previously vaccinated or exposed. The rate and degree depend on diagnosis, age, type of donor, stem cell source, administration of rituximab during transplantation, incidence of GvHD and degree of immunity present before HSCT. 1 Increasing recipient pretransplantation immunity through early vaccination or donor vaccination could theoretically attenuate this anticipated immune decline. This is most important for infections that may occur early after transplant and then cause significant morbidity and mortality such as pneumococcal infections and influenza.
Pathogens encountered pretransplantation that can induce T-cell response to vaccines at 1-6 months post transplantation and Ab response 3-12 months post transplantation. [2] [3] [4] Most of the circulating T cells in the first year after transplantation are T cells derived from the graft that are capable of reacting to Ags exposed to the donor before transplantation. 5 Therefore, prior pathogen exposure to HSCT is beneficial in inducing T-cell and Ab response to vaccinations administered post HSCT.
Like infants, HSCT recipients respond poorly to polysaccharide Ags (for example, the 23-valent polysaccharide pneumococcal vaccine) and to poorly immunogenic protein neoantigens (for example, HBsAg). 2, 6, 7 However, more highly immunogenic protein Ags (for example, tetanus toxoid) and polysaccharide-protein conjugates (for example, Haemophilus influenzae type B vaccine) can elicit Ab responses earlier in post-HSCT patients and increase immune responses for immunosuppressed patients. 8 This paper attempts to explore the evidence behind preHSCT vaccination in donors and recipients of HSCT as well as address the ethical, medical and logistical complexities involved in this type of vaccination schedule.
AVAILABLE DATA USING PRETRANSPLANT VACCINATIONS Pneumococcal Pneumonia, sepsis and meningitis secondary to Streptococcus pneumoniae occur at an incidence of 0.9-4% in transplant patients, and result in significant morbidity and mortality. [9] [10] [11] [12] The median onset of invasive diseases occur 1 year post HSCT, although infections occur also early after HSCT. [10] [11] [12] [13] Vaccination before transplant in both donors and recipients has shown to influence Ab responses post transplant. 9, 14, 15 In the United States, there are currently two pneumococcal vaccinations available that include the PCV13 (pneumococcal conjugate vaccine) and the PPV23 (pneumococcal polysaccharide vaccine). The Food and Drug Administration approved the PCV13 vaccine in 2011 for prevention of pneumonia and invasive disease caused by PCV13 serotypes among adults ⩾ 50 years of age. This vaccine replaced the PCV7 (heptavalent pneumococcal conjugate) vaccine. In mid-2010 European countries started to switch to vaccines covering more serotypes (PCV10/PCV13).
In a randomized, double-blind trial comparing preHSCT donor vaccination of PCV7 with PPV23, donor vaccination improved the early response but there was no difference at 1 year post transplantation.
14 In addition, Antin et al. 15 randomized 61 patients undergoing autologous HSCT to receive PCV7 or no vaccine before collection of HSCT. All study patients then received 1 PCV7 at 3, 6 and 12 months post transplant. At 3, 6, 12 and 13 months, there were significantly higher serotype-specific Ab concentrations in the pretransplant vaccinated group. 15 Furthermore, Molrine et al. 9 evaluated the PCV7 administration in 43 recipients of matched-related donor HSCT and determined that Ab concentrations to six serotypes in PCV7 were significantly higher in recipients after one and two doses of the vaccine post transplant if the donor had been immunized before transplant. 9 This result suggests that immunity was transferred to the HSCT recipients and enhanced their responses to additional vaccine doses administered to the HSCT recipients post transplantation. However, no study has compared this strategy with an early post-HSCT vaccination strategy as studied by Cordonnier et al. Diphtheria-tetanus-pertussis There are two types of diphtheria and tetanus vaccines, DT and Td. DT includes full-dose diphtheria toxoid, whereas Td has reduced dose diphtheria. DT is not approved for adults in the United States due to adverse effects associated with the vaccine. However, both previous and current guidelines recommend the use of the DT vaccine in SCT recipients. 16 The Center for Disease Control in the United States currently recommends Tdap (tetanus-diphtheriaacellular pertussis) 10 years after Td in adults due to the steady increase of pertussis in the population. Several studies have shown that donor vaccination improves the likelihood of transfer of immunity. [17] [18] [19] [20] Storek et al. 19 determined that Ab levels post HSCT are improved by vaccinating the donor (20 days before HSCT) as well as the recipient (1 day before HSCT and 50 days post HSCT) for tetanus. Parkkali et al. 20 found that donor vaccination resulted in significantly higher Ab concentrations for diphtheria at 6 and 13 months post HSCT. It is unknown whether donor vaccination for pertussis improves Ab responses in transplant recipients. A future study may help to answer this issue.
Influenza
The current influenza vaccination recommendations are for yearly seasonal administration of the influenza vaccine beginning before HSCT and resuming at 4-6 months after transplantation. 16 Patients preparing for HSCT, however, should only receive the inactivated vaccine. 21 Preliminary data from a randomized study combining donor vaccination with recipient vaccination at 6 months after HSCT showed poor results with this strategy. 22 It is possible that earlier post-transplant vaccination would have given better responses but this needs to be studied further.
Varicella
Varicella zoster virus (VZV) reactivation causes herpes zoster infection in 23-50% of bone marrow transplantation (BMT) recipients during the first year after transplantation. 23 Severe morbidity occurs when cranial nerves are involved, secondary bacterial infections occur, or when patients suffer from postherpetic neuralgia. Long-term acyclovir prophylaxis is effective in preventing reactivation. [24] [25] [26] Most episodes of herpes zoster in the absence of acyclovir prophylaxis occur within the first 2-10 months after transplantation and T-cell responses to VZV Ag encountered pretransplant can be detected as early as 1-6 months post transplant. 23, 27 Therefore, vaccination of both donors and recipients could be a strategy worth studying further. However, the currently existing vaccines are live and therefore contraindicated in immunosuppressed individuals; but a heatinactivated virus could eliminate that risk. Hata et al. 28 showed that heat-inactivated varicella vaccine, when given 30 days before autologous BMT and during the first 90 days after transplant, reduces the risk of zoster. In a study evaluating safety and immunogenicity of four doses of heat-treated zoster vaccine, the first of which was given at 30 days before SCT, the results indicated that autologous but not allogeneic HSCT recipients had a rise in VZV-specific T-cell response. 29 This vaccine and another inactivated vaccine are in phase III clinical trials in immunocompromised patients and might be used for donor/recipient vaccination studies. However, the strategy to vaccinate patients after discontinuation of antiviral prophylaxis should also be explored.
Hepatitis B Hepatitis B can cause fulminant liver failure and is a risk for previously hepatitis B virus (HBV)-infected immunosuppressed patients in whom the virus can reactivate. Therefore, antiviral prophylaxis is recommended after HSCT to an HBV-infected patient. Full immunization for hepatitis B is normally three injections over 6 months and therefore can be difficult to arrange when HSCT is time sensitive. Ilan et al. 30 found that immunity against HBV can be transferred through active immunization of donors with a booster vaccination of recipients. Moreover, pretransplant immunizations in both donor and recipient were found to potentiate Ab response post transplantation. 17 However, Storek et al. 19 did not find that preHSCT donor and recipient vaccination resulted in detectable levels of antibodies. As HbsAg is a poorly immunogenic protein neoantigen, it is conceivable that repetitive donor vaccination may result in higher Ab titers and thus higher transfer of immunity. 19 Donor and recipient vaccination preSCT may result in further immunoprotection against HBV.
Measles, mumps and rubella Fortunately, measles, mumps and rubella infections are seen rarely in bone marrow transplant patients mainly due to a high degree of vaccine coverage of the general population. However, outbreaks of measles have occurred in several countries in recent years thereby increasing the risk for infections in HSCT patients not protected against measles. As measles, mumps and rubella is a live attenuated vaccine, it should not be administered during immunocompromised states such as in the preparatory phase for HSCT. As HSCT patients often lose their seropositivity post transplant, there is a concern that these patients can be at risk for developing infection within 5 years of their transplant. 31, 32 The strongest risk factor for losing seropositivity post transplant is younger age presumably due to vaccine induced immunity rather than immunity caused by measles infection. 33 Wahren et al. 34 showed that the probability of retaining antibodies in the first year post transplant is highest if the donor and recipient are seropositive for a virus pretransplant. Most donors will be seropositive to measles due to either previous measles infection or vaccination. Whether an additional dose of vaccine given before donation would be beneficial is unknown and needs to be studied. 33, 35 Vaccination of HSCT recipients not having chronic GvHD or ongoing immune suppression is recommended at 2 years post transplantation. 16 Hib Haemophilus influenzae can cause pneumonia post transplant and its encapsulated type b (Hib) is its most virulent strain. 36 Donor immunization, however, can boost protective immunity for immunocompromised patients. 37 Storek et al. 19 determined that Ab levels post transplant are improved by vaccinating the donor (20 days before transplant) as well as the recipient (1 day before transplant and 50 days post transplant) for H. influenzae. Parkkali et al. 20 also confirmed that Hib Ab concentrations were significantly higher 12 months post transplant when the patient received a graft from a vaccinated donor. Donor vaccination also improved Ab concentrations in patients who developed acute GvHD, a patient population who is especially at risk for infections due to their immunocompromised status. 20 Therefore, preHSCT vaccination in both donors and recipients may be beneficial although early severe Hib infections seem to be rare.
DISCUSSION
Vaccinating donors and transplant recipients preHSCT may be a potentially attractive strategy to augment immunity post HSCT as Ags retained in the recipient can stimulate proliferation of lymphocytes transferred from the donor. It should be recognized that until now existing studies have not shown any beneficial effect on the risk for infection and have all used surrogate endpoints, for example, immune responses ( Table 1) . The same limitation is true of most studies of recipient vaccination. The unmet medical need is highest for pneumococcal infections and influenza since these can cause severe early disease after HSCT.
For other vaccines such as diphtheria and tetanus, the improved transfer of immunity is more of theoretical interest since the risk for a SCT patient to develop these infections is extremely small ( Table 1) .
Transfer of B-cell-mediated immunity is dependent on the number and strength of exposures to the Ag pretransplant as well as the chemical structure of the Ag. 19 Recipient and donor immunization pretransplant to protein recall Ags (for example, tetanus toxoid) and polysaccharide-protein conjugate vaccines (for example, Hib) were shown to improve post transplant Ab levels, but immunization against polysaccharide Ags has not. Therefore, investigative innovation should be directed to developing more immunogenic vaccines, for example, proteinconjugated Ags.
There are obvious limitations for preHSCT vaccinations. The window of opportunity for vaccinating recipients pretransplant is very limited for most patients due to therapy given for their underlying malignancies until very close before the SCT although in patients with non-malignant or more indolent malignancies, the opportunity exists. For unrelated donors, vaccination may be entirely unfeasible. In addition, the vaccine itself can be associated with adverse events such as a local reaction with or without associated infection, which could in theory postpone HSCT. Furthermore, additional vaccination will increase the cost and it may be difficult to obtain coverage for vaccinations in the donor population when there may not be a health benefit for the donor. It also evokes the question of whether it is ethical to vaccinate a population that may not derive any health benefit or that could even put them at risk of side effects.
Live vaccines also can never be administered to an immunocompromised patient, such as patients preparing for HSCT, as the pathogen can undergo uninhibited replication resulting in infection. 16, 38 Furthermore, a certain level of Ab in response to a vaccine presumes immunity but protection against disease cannot be confirmed. In addition, the timing of Ag exposure may not align with induction of immunity in such severely immunocompromised patients. Finally, despite optimal attempts at early donor-recipient vaccination, a large portion of immunity will inevitably be lost through transplantation. Abbreviations: HBV = hepatitis B vaccine; HSCT = hematopoietic cell transplantation; MMR = measles, mumps and rubella; PCV7 = heptavalent pneumococcal conjugate.
CONCLUSION Pre-HSCT vaccination in both donors and recipients is an attractive strategy to prevent infections to pathogens that can cause significant morbidity and mortality. More immunogenic vaccines such as protein-conjugating polysaccharide Ags should be developed so that patients (and donors) can develop a more robust immunogenic response to the vaccine pretransplantation and studies performed to assess immunogenicity in the HSCT patient population. In the interim, focus should be placed on thorough evaluation of the donor and recipient immunization status pretransplant in order to fully prepare and administer prophylaxis for important pathogens encountered in the early post transplant period.
